Concepedia

Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma

Ilya Tsimafeyeu, Lev Demidov, Galina Kharkevich, Natalia N. Petenko, Vladimir Galchenko, Igor Sinelnikov, Uladzislau Naidzionak

American Journal of Clinical Oncology · 2011 · 24 citations · 13 references

DOI

Abstract

Capecitabine has clinical activity in MRCC patients who have non-clear cell histology and a good or intermediate prognosis. Additional prospective randomized trial comparing capecitabine with placebo is required.

References

13

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations

Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology

Robert J. Motzer, Jennifer Bacik, Tania Mariani et al. · Journal of Clinical Oncology · 2002 · 495 citations

Thymidine phosphorylase is angiogenic and promotes tumor growth.

Amir Moghaddam, H T Zhang, Tai‐Ping Fan et al. · Proceedings of the National Academy of Sciences · 1995 · 391 citations · Full text

Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity

Amir Moghaddam, Roy Bicknell · Biochemistry · 1992 · 208 citations

Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity

Kensuke Usuki, Jan Saras, Johannes Waltenberger et al. · Biochemical and Biophysical Research Communications · 1992 · 198 citations

, , +7